Lonza Pharma & Biotech

April 24, 2018
Lonza Pharma & Biotech

Sponsored Content

Due to the intrinsic enteric properties of Capsugel® Vcaps® Enteric, no coating step is needed. It means that this capsule is a ready-to-use solution that can help you in obtaining significant cost and time savings during pharmaceutical development or compounding.

Capsugel® Vcaps® Enteric Capsule is a fully compliant capsule technology that simplifies drug enteric delivery implementation from early-stage development to commercial manufacturing. The pharmaceutical grades of cellulosic derivatives used in Capsugel® Vcaps® Enteric capsules are approved and have extensive market precedence for use in providing enteric protection. They have been evaluated in-vitro and in-vivo across a number of compounds, which has proven full compliance with relevant European, Japanese and US Pharmacopeia monographs.

 

Capsugel® Vcaps® Enteric capsules can be utilized to greatly simplify and accelerate prototype development and rapid in-vivo testing of products requiring targeted delivery to the upper GI tract:

  • Eliminate coating system preparation and application steps


  • Rapid screening and optimization of enteric performance


  • Remove dependency of enteric functionality with process variability


  • Obviate need for process development of the enteric coating step, process scale-up and validation

Product Description

  • Two-piece hard capsule


  • Manufactured with pharmaceutical-grade cellulosic derivatives (HPMCAS, HPMC)

 

Contact Details:

Company name: Lonza Pharma & Biotech
Website: www.capsugel.com/biopharmaceutical-products/vcaps-enteric-capsules
E-mail: solutions.emea@lonza.com